EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preliminary Analytical Verification of the Automated Cobas i601 LC-MS/MS System for Immunosuppressant Quantification in a Clinical Laboratory

Mariana Serres-Gómez iD, María Gemma Serrano Olmedo iD, María Luisa González-Casaus iD, Belén Fernández-Puntero iD, Pilar Fernández-Calle iD, Lucía Díaz García iD, Ana Rejas Muslera iD, Jon Sánchez-Munárriz iD, Antonio Buño Soto iD

Journal of Mass Spectrometry and Advances in the Clinical Lab · 19.05.2026 · 39 (1)

DOI: 10.21627/rtbk5y18 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Mass Spectrometry and Advances in the Clinical Lab, online erschienen am 19.05.2026. Verfasst von Mariana Serres-Gómez und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, La Paz University Hospital, Madrid, 28046, Spain. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Therapeutic drug monitoring (TDM) of immunosuppressive drugs is essential to maintain concentrations within narrow therapeutic windows and minimize toxicity. Automated LC–MS/MS platforms can combine the analytical specificity of mass spectrometry with workflow efficiency suitable for routine laboratories. OBJECTIVES: To preliminarily evaluate the analytical performance of the Cobas i601 automated LC–MS/MS system for quantifying tacrolimus, cyclosporine, everolimus, and sirolimus and to compare results with routine immunoassays and an LC–MS/MS method for sirolimus. METHODS: Imprecision, bias, and linearity were assessed according to the Clinical Laboratory Standards Institute (CLSI) EP10-A3 standard using quality-control materials. Method comparison and bias estimation versus the Dimension EXL 200 immunoassays and an LC–MS/MS technique for sirolimus followed the CLSI EP09-A3 standard. Regression analyses and predicted biases at therapeutic range concentrations were compared with allowable limits. RESULTS: The Cobas i601 showed good precision and linearity, meeting manufacturer specifications. The highest coefficients of variations for tacrolimus, everolimus, cyclosporine, and sirolimus were 4.0%, 4.7%, 3.6%, and 4.8%, and the maximum EP10-A3 biases were −7.4%, −3.9%, 4.7%, and 5.4%, respectively. In the method comparison, tacrolimus, everolimus, and cyclosporine showed substantial negative biases versus immunoassays (−22.7%, −38.9%, and −37.5%), exceeding allowable limits. Sirolimus exhibited smaller positive bias relative to the LC–MS/MS method (12.5%). Interchangeability between the methodologies cannot be assumed. CONCLUSION: The Cobas i601 provides reliable automated LC–MS/MS quantification of immunosuppressants, with good precision and linearity. Method-dependent biases highlight the need for careful interpretation during technology transitions. The Cobas i601 shows strong potential for routine LC–MS/MS implementation in TDM in clinical laboratories.

Schlagwörter

Stichwörter der Autor:innen

Therapeutic drug monitoringautomationimmunoassayimmunosuppressantsliquid chromatography–tandem mass spectrometry

Autor:innen und Institutionen

  • Department of Laboratory Medicine, La Paz University Hospital, Madrid, 28046, Spain.
  • IdiPaz-Hospital La Paz Institute for Health Research, Madrid, 28046, Spain.
  • Department of Laboratory Medicine, La Paz University Hospital, Paseo de la Castellana 261, Madrid, 28046, Spain.
  • Department of Clinical Pharmacology, La Paz University Hospital, Madrid, 28046, Spain.
  • Department of Laboratory Medicine, 12 de Octubre University Hospital, Madrid, 28041, Spain.

ORCID-Profile: Mariana Serres-Gómez, María Gemma Serrano Olmedo, María Luisa González-Casaus, Belén Fernández-Puntero, Pilar Fernández-Calle, Lucía Díaz García, Ana Rejas Muslera, Jon Sánchez-Munárriz, Antonio Buño Soto

Zitieren

APA

Serres-Gómez, M., Gemma Serrano Olmedo, M., Luisa González-Casaus, M., Fernández-Puntero, B., Fernández-Calle, P., Díaz García, L., Muslera, A. R., Sánchez-Munárriz, J., & Buño Soto, A. (2026). Preliminary Analytical Verification of the Automated Cobas i601 LC-MS/MS System for Immunosuppressant Quantification in a Clinical Laboratory. Journal of Mass Spectrometry and Advances in the Clinical Lab, 39(1). https://doi.org/10.21627/rtbk5y18

Vancouver

Serres-Gómez M, Gemma Serrano Olmedo M, Luisa González-Casaus M, Fernández-Puntero B, Fernández-Calle P, Díaz García L, et al. Preliminary Analytical Verification of the Automated Cobas i601 LC-MS/MS System for Immunosuppressant Quantification in a Clinical Laboratory. Journal of Mass Spectrometry and Advances in the Clinical Lab. 2026;39(1). doi:10.21627/rtbk5y18

BibTeX
@article{SerresGmez2026,
  author = {Serres-Gómez, Mariana and Gemma Serrano Olmedo, María and Luisa González-Casaus, María and Fernández-Puntero, Belén and Fernández-Calle, Pilar and Díaz García, Lucía and Muslera, Ana Rejas and Sánchez-Munárriz, Jon and Buño Soto, Antonio},
  title = {Preliminary Analytical Verification of the Automated Cobas i601 LC-MS/MS System for Immunosuppressant Quantification in a Clinical Laboratory},
  journal = {Journal of Mass Spectrometry and Advances in the Clinical Lab},
  year = {2026},
  volume = {39},
  number = {1},
  doi = {10.21627/rtbk5y18}
}
Kostenlos starten →